. 2022 Jul 31;12(8):e943. doi: 10.1002/ctm2.943

TABLE 1.

Overview of all CD47‐signal regulatory protein alpha (SIRPα) blocking antibodies that are or have been in clinical trials

Name	Format	Target	Isotype	Cotreatment	Type of cancer	Progress	Start date	(Expected) completion date	NCT/CRT	Company
AK117 ²⁶	CD47 mAb	CD47	IgG4	Azacitidine	Acute myeloid leukaemia	Phase I/II clinical	Jun‐21		CTR20211305	Akeso
AK117 ²⁶	CD47 mAb	CD47	IgG4	Monotherapy	Advanced cancer	Phase I clinical	Jan‐21	1‐Jan‐23	NCT04728334	Akeso
AK117 ²⁶	CD47 mAb	CD47	IgG4	Monotherapy	Advanced solid cancer, non‐Hodgkin lymphoma	Phase I clinical	Dec‐20		CTR20202684	Akeso
AK117 ²⁶	CD47 mAb	CD47	IgG4	Azacitidine	Myelodysplastic syndrome	Phase I/II clinical	May‐21	May‐24	NCT04900350	Akeso
AK117 ²⁶	CD47 mAb	CD47	IgG4	Azacitidine	Myelodysplastic syndrome	Phase I/II clinical	May‐21		CTR20210825	Akeso
AO‐176 ²⁵	CD47 mAb	CD47	IgG2	Monotherapy, paclitaxel, pembrolizumab	Advanced solid cancer	Phase I/II clinical	Feb‐19	Mar‐23	NCT03834948	Arch Oncology
AO‐176 ²⁵	CD47 mAb	CD47	IgG2	Monotherapy, bortezomib, bortezomib + dexamethasone	Multiple myeloma	Phase I/II clinical	Nov‐20	Mar‐23	NCT04445701	Arch Oncology
CC‐90002 ¹⁴	CD47 mAb	CD47	IgG4	Monotherapy	Acute myeloid leukemia, myelodysplastic syndrome	Phase I clinical	Mar‐16	Ended preliminary	NCT02641002	Celgene
CC‐90002 ¹⁴	CD47 mAb	CD47	IgG4	Rituximab	Haematological cancer	Phase I clinical	Mar‐15	Feb‐22	NCT02367196	Celgene
CPO107/JMT601	CD20/CD47	CD47	bsAb	Monotherapy	Advanced CD20‐positive non‐Hodgkin lymphoma	Phase I clinical	Aug‐21	Aug‐24	NCT04853329	Conjupro Biotherapeutics
DSP‐107 ¹¹⁰	rhSIRPα/4‐1BB	CD47	bsAb	Monotherapy, atezolizumab	Advanced solid cancer, non‐small cell lung cancer	Phase I clinical	Oct‐20	Aug‐23	NCT04440735	Kahr medical
Hu5F9‐G4 (Magrolimab) ¹⁸	CD47 mAb	CD47	IgG4	Cetuximab	Advanced solid cancer and advanced colorectal cancer	Phase I/II clinical	Nov‐16	10‐Feb‐20	NCT02953782	Stanford University Forty Seven
Hu5F9‐G4 (Magrolimab) ¹⁸	CD47 mAb	CD47	IgG4	Rituximab	B‐cell non‐Hodgkin lymphoma	Phase I/II clinical	Nov‐16	Nov‐21	NCT02953509	Stanford University Forty Seven
Hu5F9‐G4 (Magrolimab) ¹⁸	CD47 mAb	CD47	IgG4	Obinutuzumab, venetoclax	Follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma	Phase I clinical	Oct‐20	Jun‐21	NCT04599634	National cancer institute (NCI)
Hu5F9‐G4 (Magrolimab) ¹⁸	CD47 mAb	CD47	IgG4	Azacitidine	Haematological cancer	Phase I clinical	Sep‐17	Aug‐21	NCT03248479	Stanford University Forty Seven
Hu5F9‐G4 (Magrolimab) ¹⁸	CD47 mAb	CD47	IgG4	Pembrolizumab	Hodgkin lymphoma	Phase II clinical	Nov‐21	Dec‐22	NCT04788043	Stanford University Forty Seven
Hu5F9‐G4 (Magrolimab) ¹⁸	CD47 mAb	CD47	IgG4	Avelumab	Ovarian cancer	Phase I clinical	May‐18	1‐Dec‐20	NCT03558139	Stanford University Forty Seven
HX009 ¹⁰⁵	CD47‐PDL‐1	CD47	bsAb	Monotherapy	Advanced solid cancer	Phase II clinical	Jun‐21		CTR20211292	Waterstone Hanxbio Pty Ltd.
HX009 ¹⁰⁵	CD47‐PDL‐1	CD47	bsAb	Monotherapy	Advanced solid cancer	Phase I clinical	Jun‐19	Sep‐21	NCT04097769	Waterstone Hanxbio Pty Ltd.
IBI188 (Letaplimab)	CD47 mAb	CD47	IgG4	Azacitidine, decitabine	Acute myeloid leukaemia	Phase 1/2 clinical	Jul‐20		CTR20200938	Innovent Biologics
IBI188 (Letaplimab)	CD47 mAb	CD47	IgG4	Azacitidine	Acute myeloid leukaemia and myelodysplastic syndromes	Phase I clinical	Apr‐21		CTR20210761	Innovent Biologics
IBI188 (Letaplimab)	CD47 mAb	CD47	IgG4	Monotherapy, rituximab	Advanced cancer	Phase I clinical	Dec‐18	Jan‐22	NCT03717103	Innovent Biologics
IBI188 (Letaplimab)	CD47 mAb	CD47	IgG4	Monotherapy	Advanced solid cancer	Phase I clinical	Nov‐18		CTR20182140	Innovent Biologics
IBI188 (Letaplimab)	CD47 mAb	CD47	IgG4	Monotherapy	Advanced solid cancer and lymphoma	Phase I clinical	Jan‐19	Aug‐22	NCT03763149	Innovent Biologics
IBI188 (Letaplimab)	CD47 mAb	CD47	IgG4	Azacitidine	Myelodysplastic syndrome	Phase 1/3 clinical	Jul‐20		CTR20201039	Innovent Biologics
IBI‐322 ¹⁰⁴	CD47‐PD‐1	CD47	IgG	PD‐1/CD47 bsAb, single agents	Advanced solid cancer	Phase I clinical	Jun‐21	Jun‐23	NCT04912466	Innovent Biologics
IBI‐322 ¹⁰⁴	CD47‐PD‐1	CD47	IgG	PD‐1/CD47 bsAb, single agents	Advanced solid cancer	Phase I clinical	Apr‐21	Dec‐22	NCT04338659	Innovent Biologics
IBI‐322 ¹⁰⁴	CD47‐PD‐1	CD47	IgG	PD‐1/CD47 bsAb, single agents	Advanced solid cancer	Phase I clinical	Jul‐20	Sep‐23	NCT04328831	Innovent Biologics
IBI‐322 ¹⁰⁴	CD47‐PD‐1	CD47	IgG	PD‐1/CD47 bsAb, single agents	Haematological cancer	Phase I clinical	May‐21	Nov‐23	NCT04795128	Innovent Biologics
IBI‐322 ¹⁰⁴	CD47‐PD‐1	CD47	IgG	PD‐1/CD47 bsAb, azacitidine/decitabine	Myeloid tumour	Phase I clinical	Dec‐21	Jun‐23	NCT05148442	Innovent Biologics
IMC‐002 ⁸	CD47 mAb	CD47	IgG4	Monotherapy	Metastatic/locally advanced solid tumours, relapsed or refractory lymph	Phase I clinical	Jun‐20	Dec‐22	NCT04306224	ImmuneOncia
IMM0306	CD47‐CD20	CD47	IgG1	Monotherapy	Non‐Hodgkin lymphoma	Phase I clinical	May‐20		CTR20192612	ImmuneOnco Biopharma
IMM2902	HER2/rhSIRPα	CD47	bsAb	Monotherapy	Advanced solid cancer	Phase I clinical	Jan‐22	Jun‐23	NCT05076591	ImmuneOnco Biopharma
PF‐07257876	CD47/PD‐L1	CD47	bsAb	Monotherapy	Non‐small cell lung cancer, squamous cell carcinoma of the head and neck	Phase I clinical	Jun‐21	Apr‐24	NCT04881045	Pfizer
SGN‐CD47 M	ADC‐CD47	CD47	Unknown	Monotherapy	Advanced solid cancer	Phase I clinical	Jul‐19	Sep‐20	NCT03957096	Seagen
SHR‐1603	CD47 mAb	CD47	IgG4		Advanced solid cancer	Phase I clinical	Nov‐18	On hold	CTR20181964	Jiangsu HengRui Medicine
SRF231 ¹³	CD47 mAb	CD47	IgG4	Monotherapy	Advanced cancer	Phase I/Ib clinical	Apr‐18	1‐9‐2020 ended without results	NCT03512340	Surface Oncology
STI‐6643	CD47 mAb	CD47	IgG4	Monotherapy	Advanced solid cancer	Phase I clinical	Aug‐21	Dec‐22	NCT04900519	Sorrento therapeutics
TBQ2928	Unknown	CD47	Unknown	Monotherapy	Advanced cancer	Phase I clinical	Aug‐21	Dec‐22	NCT04854681	Chia Tai Tianqing Pharmaceutical Group
TG‐1801 ⁴³	CD47‐CD19	CD47	IgG1 bsAb	Ublituximab, umbralisib	B‐cell lymphoma	Phase I clinical	Mar‐19	1‐Aug‐21	NCT03804996	Novimmune TG Therapeutics
TG‐1801 ⁴³	CD47‐CD19	CD47	IgG1 bsAb	Ublituximab	B‐cell lymphoma, chronic lymphocytic leukaemia	Phase I clinical	Apr‐21	Dec‐23	NCT04806035	Novimmune TG Therapeutics
TI‐061 ¹⁵	CD47 mAb	CD47	IgG4	Pembrolizumab	Solid cancer and breast cancer	Phase I/II clinical		Ended preliminary		Arch Oncology
TJ011133 (Lemzoparlimab) ²⁷	CD47 mAb	CD47	IgG4	Monotherapy	Acute myeloid leukaemia and myelodysplastic syndromes	Phase I/II clinical	Mar‐20	Aug‐23	NCT04202003	I‐MAB Biopharma
TJ011133 (Lemzoparlimab) ²⁷	CD47 mAb	CD47	IgG4	Monotherapy	Acute myeloid leukaemia and myelodysplastic syndrome	Phase I/II clinical	Dec‐12		CTR20192522	I‐MAB Biopharma
TJ011133 (Lemzoparlimab) ²⁷	CD47 mAb	CD47	IgG4	Azacitidine	Acute myeloid leukaemia/myelodysplastic syndrome	Phase I/II clinical	Mar‐21		CTR20210555	I‐MAB Biopharma
TJ011133 (Lemzoparlimab) ²⁷	CD47 mAb	CD47	IgG4	Pembrolizumab, rituximab	Advanced solid cancer and lymphoma	Phase I clinical	May‐19	Sep‐23	NCT03934814	I‐MAB Biopharma
TJ011133 (Lemzoparlimab) ²⁷	CD47 mAb	CD47	IgG4	Rituximab	Lymphoma, CD20+	Phase I clinical	Mar‐21		CTR20210313	I‐MAB Biopharma
TTI‐621 ¹²	SIRPα‐Fc	CD47	IgG1	PD‐1/PD‐L1 inhibitor, pegylated interferon α2a, ta	Advanced solid cancer and mycosis fungoides	Phase I clinical	Sep‐16	Mar‐20	NCT02890368	Trillum Therapeutics
TTI‐621 ¹²	SIRPα‐Fc	CD47	IgG1	Monotherapy, rituximab, nivolumab	Haematological cancer and selected solid tumours	Phase I/Ib clinical	Jan‐16	Dec‐21	NCT02663518	Trillum Therapeutics
TTI‐621 ¹²	SIRPα‐Fc	CD47	IgG1	Doxorubicin	Leiomyosarcoma	Phase I/II clinical	Jun‐21	Jun‐23	NCT04996004	Trillum Therapeutics
TTI‐622 ¹⁹	SIRPα‐Fc	CD47	IgG4	Rituximab, PD‐1 inhibitor, proteasome inhibitor re	Lymphoma or myeloma	Phase I clinical	May‐18	30‐Apr‐22	NCT03530683	Trillum Therapeutics
ZL‐1201	CD47 mAb	CD47	IgG4	Monotherapy	Advanced cancer	Phase I clinical	May‐21		CTR20210973	Zai Lab
ZL‐1201	CD47 mAb	CD47	IgG4	Monotherapy	Advanced cancer	Phase I clinical	May‐20	1‐Jan‐24	NCT04257617	Zai Lab
ALX148 (Evorpacept) ³²	SIRPα‐D1	SIRPα	IgG1 (inactive)	Venetoclax, azacitidine	Acute myeloid leukemia	Phase I/II clinical	May‐21	Dec‐23	NCT04755244	ALX oncology
ALX148 (Evorpacept) ³²	SIRPα‐D1	SIRPα	IgG1 (inactive)	Pembrolizumab, trastuzumab, rituximab, ramucirumab	Advanced solid cancer and lymphoma	Phase I clinical	Feb‐17	Dec‐21	NCT03013218	ALX oncology
ALX148 (Evorpacept) ³²	SIRPα‐D1	SIRPα	IgG1 (inactive)	Trastuzumab, ramucirumab, paclitaxel	Gastric cancer, gastroesophageal junction adenocarcinoma, gastric adenocarcinoma	Phase II/III clinical	Aug‐21	Jul‐26	NCT05002127	ALX oncology
ALX148 (Evorpacept) ³²	SIRPα‐D1	SIRPα	IgG1 (inactive)	Pembrolizumab, 5‐fluoruracil, cisplatin	Head and neck cancer	Phase 2 clinical	Jun‐42	Oct‐24	NCT04675333	ALX oncology
ALX148 (Evorpacept) ³²	SIRPα‐D1	SIRPα	IgG1 (inactive)	Rituximab, lenalidomide	Indolent and aggressive B‐cell non‐Hodgkin lymphoma	Phase I/II clinical	Sep‐21	Mar‐26	NCT05025800	M.D. Anderson Cancer Center
ALX148 (Evorpacept) ³²	SIRPα‐D1	SIRPα	IgG1 (inactive)	Azacitidine	Myelodysplastic syndrome	Phase I/II clinical	Oct‐20	Dec‐23	NCT04417517	ALX oncology
BI765063/OSE‐172 ³⁶	SIRPα‐D1	SIRPα	IgG1	PD‐1 antagonist	Advanced solid cancer	Phase I clinical	Apr‐19	Dec‐22	NCT03990233	OSE Immunotherapeutics
CC‐95251	SIRPα	SIRPα		Rituximab, cetuximab	Advanced cancer	Phase I	Feb‐19	Nov‐24	NCT03783403	Celgene
IMM01	SIRPα	SIRPα	IgG1	Monotherapy	Non‐Hodgkin lymphoma	phase I clinical	Aug‐21	Jan‐22	CTR20191531	ImmuneOnco Biopharma
SL‐172154¹⁰⁸	SIRPα‐CD40	SIRPα	Fusion protein	Monotherapy	Gynaecological tumours	Phase I clinical	Jun‐20	Jun‐22	NCT04406623	Shattuck lab
SL‐172154 ¹⁰⁸	SIRPα‐CD40	SIRPα	Fusion protein	Monotherapy	Skin, head and neck cancer	Phase I clinical	Sep‐20	Jul‐22	NCT04502888	Shattuck lab

Note: These antibodies are designed with different Fc domains as described in the fourth column. Within these clinical trials, CD47/SIRPα blockade is often evaluated with cotreatment with other monoclonal antibodies, chemotherapy, demethylating agents and/or proteosome inhibitors. Clinical trials with CD47 blocking are conducted in a host of different tumour types.

Abbreviations: bsAb, bispecific antibody; HER2, human epidermal growth factor receptor 2; Ig, immunoglobulin; mAb, monoclonal antibody; PD‐(L)1, programmed cell death (ligand)1; (rh)SIRPα, (recombinant human)SIRPα.

Source: CD47‐related clinical trials registered in US national clinical trials registry (NCT) system (www.clinicaltrials.gov) or in the China drug trials registry (CDT) system (www.chinadrugtrials.org.cn).